A Chitosan-DNA Mucosal Vaccine for Respiratory Syncytial Virus Infection

A gene expression vaccine (GXV) comprising of a cocktail of pDNAs encoding nine immunogenic antigens was developed in the form of chitosan-DNA nanospheres. This GXV was tested in a BALB/c model of RSV infection. Results demonstrate that an intranasal GXV is safe and effective against RSV and significantly attenuates pulmonary inflammation induced by RSV infection. Description (Set) Proposed Use (Set) Prophylactic and therapeutic vaccine Patent (Set) 7,118,888; WO 03/028759

Patents:
US 7,118,888

Inventor(s): Huang, Shau-Ku

Type of Offer: Licensing



« More Medical Devices Patents

---